• About
    • Leadership
    • Medical Advisory Board
    • Conditions We Treat
    • Careers
  • Science
    • Product
    • Procedure
    • History
  • Clinical Trials
  • Press
    • Allotex in the News
    • Press Releases
    • Media Assets
  • Contact
  • Menu
  • Skip to right header navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Allotex

Allograft Inlays & Onlays

  • About
    • Leadership
    • Medical Advisory Board
    • Conditions We Treat
    • Careers
  • Science
    • Product
    • Procedure
    • History
  • Clinical Trials
  • Press
    • Allotex in the News
    • Press Releases
    • Media Assets
  • Contact
    • Twitter

Company Overview

After more than 50 years of research, Drs. Muller and Mrochen have developed the Allotex tissue addition technology to give patients suffering from presbyopia, hyperopia, and myopia the ability to see clearly again.

Press

A pioneer in sight technology, Allotex, Inc. is a biologics company that provides the medical world with an inventive solution to presbyopia, hyperopia, and myopia: a living contact lens. This “living lens,” or corneal allograft, is created using natural human corneal tissue that has been shaped using high-precision patented and proprietary technology. These minute, living lenses (lenticules) can be placed in or on a patient’s natural cornea with the aim of reducing or eliminating the need for wearing reading glasses.

Allotex was founded in 2014 by Dr. David Muller, who also founded of Summit Technology, the first company to get FDA approval for laser vision correction. More recently Dr. Muller founded Avedro, Inc., a combination drug and device company that just received FDA approval and Orphan Drug Designation for corneal collagen cross-linking.

Dr. Muller was joined at Allotex in 2015 by Prof. Michael Mrochen of Zurich, who has a long and esteemed track record of ophthalmic device development, particularly in the area of refractive surgery. Today Professor Michael Mrochen works in his research facility in Zurich, Switzerland, and Allotex’s production and corporate offices are in Boston, MA.

In February of 2018, Allotex closed on financing from a strategic investor to fund its upcoming European clinical trials. According to the company’s Medical Advisory Board, including Drs. Peter Hersh, Stephen Slade and Vance Thompson, “The Allotex inlay represents a major advancement in corneal tissue micro-engineering. Unlike current artificial inlays, the enhanced biocompatibility of lenticules prepared from actual corneal tissue ushers in a new era of refractive surgery by tissue addition. These novel products promise to improve the visual function of many patients.”

Primary Sidebar

Press

  • Allotex in the News
  • Press Releases
  • Media Assets

Footer

Contact

Allotex, Inc.
27-43 Wormwood Street
Suite 160
Boston MA 02210
617-391-9544

Copyright © 2014 - 2019 Allotex, Inc. · All Rights Reserved · Privacy Policy · Site design and development by Sky Dog Technologies